Status:
COMPLETED
Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment
Lead Sponsor:
Allon Therapeutics
Conditions:
Mild Cognitive Impairment, So Stated
Eligibility:
All Genders
55-85 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to find out if different doses of Investigational Drug are safe, tolerable, and if they have an effect on Mild Cognitive Impairment (MCI).
Detailed Description
Pre-Clinical experiments indicate the AL-108 compound has neuroprotective, cognitive protective and neurotrophic properties; therefore, the compound could be tested in a variety of human diseases. Hum...
Eligibility Criteria
Inclusion
- Is male or female, at 55-85 years of age (inclusive) at screening
- Self-reported memory complaint, corroborated by spouse or companion as appropriate.
- Wechsler Memory Scale III (WMS-III) age-adjusted Logical Memory II score ≤ 5.
- Mini-Mental State Exam (MMSE) ≥24.
- Center for Epidemiologic Studies-Depression (CES-D) score \<27.
- Normal thyroid function, defined as TSH, T3 and T4 within normal limits.
- Agree not to consume alcoholic beverages within 8 hours of each study visit.
- Willing and able to sign informed consent and complete the CTB and all other tests and procedures as listed in the protocol.
- Fluently reads and speaks English.
- Female subjects must be surgically sterile or post-menopausal for at least 2 years. If \<2 years post-menopausal, then a follicle stimulating hormone (FSH) ≥40 mIU/mL must be obtained.
Exclusion
- Subjects who have any significant, untreated psychiatric illness or any CNS condition (such as schizophrenia, Parkinson's disease, stroke, etc.) that could interfere with the study evaluations or procedures or which poses an additional risk. Subjects with a history of uncomplicated depression may participate if in remission and on a stable dose of antidepressant medication for at least 2 months.
- History of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities.
- History of alcohol or substance abuse or dependence within the past year.
- Acute infective sinusitis.
- History or presence of an abnormality of the external or internal structures of the nose or nasopharynx, except for surgical correction of the nasal septum or a "broken nose" at least 2 years previously, or surgical repair of cleft palate when \<30 years of age.
- Use of medications that are known to cause frank obtundation of cognition
- Use of any approved or investigational medication for Alzheimer's Disease within 3 months of screening
- History of or current significant systemic disease judged to interfere with the study evaluations or likely to be a safety concern.
- Untreated sleep apnea or treatment for sleep apnea for \<3 months.
- Abnormal clinical laboratory test results, specifically: Alanine transaminase (ALT) or aspartate transaminase (AST) \>2 х the upper limit of normal (ULN),Hematology \<80% the lower limit of normal, Creatinine ≥2 mg/dL and ,Other clinical laboratory values or vital signs considered clinically significant in the opinion of the Investigator.
- Treatment with any investigational drug, biologic, or device within the previous 30 days prior to screening.
- Surgery involving general anesthesia within the past 3 months or planned surgery requiring general anesthesia during the study period.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT00422981
Start Date
January 1 2007
End Date
January 1 2008
Last Update
October 24 2012
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Pivotal Research
Peoria, Arizona, United States, 85381
2
Collaborative Neuroscience Network
Garden Grove, California, United States, 92845
3
Synergy Research
National City, California, United States, 91950
4
Pacific Research Network, Inc
San Diego, California, United States, 92103